Vaxart Files 8-K: Shareholder Votes, Reg FD, Financials
Ticker: VXRT · Form: 8-K · Filed: Jun 2, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, regulatory-filing
Related Tickers: VXRT
TL;DR
Vaxart 8-K filed: Shareholder votes, Reg FD, financials, and past name changes detailed.
AI Summary
Vaxart, Inc. filed an 8-K on June 2, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements. The filing also notes Vaxart's former names, including Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS, with the most recent name change occurring on April 13, 2016.
Why It Matters
This 8-K filing provides updates on Vaxart's corporate governance and financial reporting, which are crucial for investors to understand the company's operational status and compliance.
Risk Assessment
Risk Level: low — This filing is primarily procedural and informational, detailing past corporate events and standard reporting requirements, rather than announcing significant new risks or developments.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Aviragen Therapeutics, Inc. (company) — Former company name
- Biota Pharmaceuticals, Inc. (company) — Former company name
- NABI BIOPHARMACEUTICALS (company) — Former company name
- June 2, 2025 (date) — Date of earliest event reported
- April 13, 2016 (date) — Date of name change
- 20160413 (date) — Date of name change
- 20121113 (date) — Date of name change
- 20100719 (date) — Date of name change
FAQ
What are the main items reported in Vaxart's 8-K filing dated June 2, 2025?
The filing reports on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements and exhibits.
When was Vaxart, Inc. previously known by other names?
Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc. (name change April 13, 2016), Biota Pharmaceuticals, Inc. (name change November 13, 2012), and NABI BIOPHARMACEUTICALS (name change July 19, 2010).
What is Vaxart's primary business classification according to the filing?
Vaxart, Inc. is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) with SIC code 2836.
What is Vaxart's business address?
Vaxart's business address is 170 Harbor Way, Suite 300, South San Francisco, CA 94080.
What is the SEC Act and file number associated with this 8-K filing?
This filing is made under the 1934 Act with SEC file number 001-35285.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 regarding Vaxart, Inc. (VXRT).